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Abstract
Background and Aims: Rotavirus causes severe diarrhoea and Brazil introduced the Rotarix G1P[8] vaccine in 2006. We
aimed to describe changes in rotavirus incidence and diarrhoea epidemiology before and after vaccine introduction.
Methods: Design: (i) hospital-based survey of children with diarrhoea (2006–2012); (ii) diarrhea-mortality and hospitalization
surveillance (1999–2012).
Setting: (i) Aracaju and (ii) state and national level.
Results: 1841 children were enrolled and 231 (12.5%) had rotavirus. Rotavirus was less frequent from January-June than
from July-December (9.4% versus 20.9%, p,0.01), but the seasonal variation was less defined after 2009. Very few rotavirus
cases (8–3.9%) were detected in 2011, with an increase in 2012 (13–18.5%). In 2006, unvaccinated children were more likely
to have rotavirus, but thereafter unvaccinated and vaccinated children had equally low incidence. Older children and those
with rotavirus were more likely to have severe diarrhea episodes. The most frequent genotype from 2006 to 2010 was
G2P[4]; except in 2009, when most cases were G1P[8]. Very few G2P[4] were detected from 2011 and 50% cases in 2012
were G8P[4]. Diarrhoea-hospitalizations decreased nationally from 89,934 (2003) to 53,705 (2012; 40.3% reduction) and in
the state from 1729 to 748 (56.7% reduction). Diarrhoea-deaths decreased nationally from 4368 in 1999 to 697 in 2012 (84%
reduction, p,0.001) and in the state from 132 to 18 (86% reduction). These changes were much larger after vaccine
introduction.
Conclusions: The vaccine was associated with substantial reductions in rotavirus incidence and diarrhoea-hospitalizations
and deaths. The G2P[4] genotype predominance disappeared over time and may be replaced by other heterotypic
genotypes.
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Introduction
The licensing of two rotavirus vaccines in 2006 and their large
scale use in countries such as Brazil and the USA marked the
beginning of a new era in paediatric diarrhoeal disease control
[1,2]. Soon after their adoption, national immunisation programs
reported significant reductions in diarrhoea-related hospitalisa-
tions and ambulatory consultations. In 2012 following pivotal
Phase III clinical trials, the World Health Organisation (WHO)
recommended extension of their use to include countries with high
diarrhoea burden in Africa and Asia [3]. Vaccine introduction in
these continents is rapidly gaining momentum with support from
international partners including the Global Alliance for Vaccines
Initiative (GAVI).
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Brazil was among the first countries to integrate a rotavirus
vaccine into its national immunisation programme, the monova-
lent G1P[8] Rotarix vaccine (Glaxo Smith Kline Biologicals) in
March 2006. Although Rotarix has good efficacy for most
homotypic genotypes (91.8% for G1P[8]), efficacy against fully
heterotypic genotype G2P[4] is only 41% [1]. Children were
offered two oral doses free of charge and vaccine coverage reached
82% by 2008 and has since remained above this level (http://
datasus.saude.gov.br/). The vaccine introduction coincided with a
decline in severe rotavirus-diarrhoea episodes, all-cause diarrhoea-
related hospitalisations and ambulatory consultations [4,5].
Although these reports were promising, Brazil reported a long-
term decline in the incidence of childhood diarrhoea [6] and a
longer period of observation was needed to elucidate the
additional contribution of rotavirus vaccine to the control of
childhood diarrhoea.
Early surveys following vaccine introduction described that
nearly all rotavirus-diarrhoea episodes were associated with the
heterotypic G2P[4] genotype [7,8]. Although this occurrence
could have been due to a temporal coincidence, as this genotype
was also circulating in several Latin American countries at that
time including some without rotavirus vaccination [9], it could also
be due to the immunological pressure exerted by the vaccine
against other genotypes for which it has higher efficacy [10]. We
now report long-term changes in the epidemiology of childhood
diarrhoea, rotavirus incidence and genotypes in the first seven
years after vaccine introduction.
Methods
Ethics statement
The study protocol was approved by the research ethics
committees of the Liverpool School of Tropical Medicine,
Sergipe’s Federal University and the Brazilian National Commis-
sion for Ethics and Research (CONEP). Parents were requested
provide written informed consent before enrolling their children in
the study.
Study design
The study comprised (i) a hospital-based survey of the
proportion, severity and genotypes of acute diarrhoea episodes
due to rotavirus among children attending a reference hospital in
Sergipe, Northeast Brazil and (ii) analysis of thirteen-year routinely
generated regional and national surveillance data comprising
seven years before and six years after rotavirus vaccine introduc-
tion.
Hospital-based survey
This was a prospective survey of children ,12 years old
presenting with diarrhea of ,14 days duration to the pediatric
emergency service of Sergipe Emergency Hospital (Hospital de
Urgeˆncias de Sergipe - HUSE) from October 2006 to April 2012.
HUSE is the largest reference hospital in Aracaju, the capital of
Sergipe State in Northeast Brazil, containing 570,937 and
2,068,031 inhabitants, respectively [11]. Although HUSE provides
24-hour services, for logistical reasons only children attending
between 8 am and 4 pm from Monday to Friday were included.
We included a sample of these children to obtain a representative
number of children for the month. We aimed to include a
minimum of 300 specimens per year, assuming the prevalence of
rotavirus would be 20% of cases per year and this sample size
would allow establishing this proportion with +/25% margin of
error. After providing informed written consent, parents and
children were interviewed to establish the clinical profile and
vaccination history. Parents were asked to collect a stool specimen
in containers before leaving the services and the approximately
60% of parents able to provide specimens were included in the
final dataset. Rotavirus vaccination status was verified against the
child’s vaccination card. In Brazil, most parents carry the child
vaccination card because this is often requested when attending
health services and it is therefore possible to confirm the
vaccination status of most children. Children with two rotavirus
vaccine doses recorded were considered vaccinated, while those
without doses or only one dose were considered unvaccinated.
Children without vaccination cards were classified as having an
unknown vaccination status.
Stools specimens were stored at 270uC until tested using an
enzyme linked immunosorbent assay (ELISA, Rotaclone; Merid-
ian Diagnostics, Cincinnati, OH). Rotavirus genotypes were
determined in ELISA-positive specimens using a hemi-nested
reverse transcription-polymerase chain reaction using consensus
and type-specific primers as described earlier [8].
Surveillance data
Rotavirus vaccine coverage data were obtained for 2007–2011
from the Expanded Program of Immunization databases at
http://pni.datasus.gov.br/inf_estatistica_cobertura.asp and mor-
tality data for 1999–2012 were obtained from the national
surveillance system (Datasus) available at http://www2.datasus.
gov.br/DATASUS/index.php?area=0205. Data were extracted
for Aracaju, Sergipe and nationally using the International
Diseases Classification (IDC) codes A08 and A09. Diarrhea-
related hospitalization data were obtained from www.datasus.gov.
br and the Hospital-based Information System (SUS-SIH/SUS)
using the IDC codes J12–J18. Data were grouped by age (,1, 1 to
4, 5 to 10 and 10 to 14 years). Frequencies for 2012 were
preliminary at the time of preparing the manuscript and thus may
be revised once officially published in its final form in the website.
Descriptive statistics were used to ascertain changes in the
distribution of diarrhea in vaccinated and unvaccinated children,
clustering of genotypes over time and their association to disease
severity. Differences in proportions were tested using Chi Squares.
Diarrhea severity was described using a frequently used severity
score [12]. Ninety five percent confidence intervals (95% CIs) and
Student’s T tests were used as appropriate.
Results
Characteristics of hospital participants
A total of 1841 children were enrolled at the HUSE survey from
October 2006 to April 2012. Most children were young, with a
median age of 12 months. Children in 2006–2009 were younger
than children in 2010–2012 (p = 0.003– table 1) and more boys
than girls were enrolled each year except in 2012. The median
diarrhea duration before consultation was 3 days and the median
number of stools before consultation varied from 4 to 5 episodes
per day over the study period. The proportion of children
vomiting was lower in 2006–2008 than in later years, increasing
from 44.4% in 2007 to 73% in 2012 (p=,0.01). The diarrhea
severity score was calculated for 1836 (99.7%) children and the
mean severity score was 10.4, ranging from 9.2 in 2008 to 12.3 in
2012. In total 1108 (59%) children had mild/moderate (score
,12) and 728 (38.9%) severe episodes (score $12). The
proportion of children with scores $12 increased over the years
from 27.6% in 2009 to 58.3% in 2012 (p,0.001). Diarrhea
severity also increased with age, with 139/466 (29.8%) children
,6 months, 160/438 (36.5%) 62,12 months old, 178/405 (44%)
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122,24 months old and 255/531 (48%) children $24 months
having severe episodes (p =,0.001).
Vaccination cards were available for 1451 (79%) children and
rotavirus vaccines were recorded in 28.8% participants in 2006
and 86.7% in 2012, with an expected increase over time (p,
0.001).
Two-hundred and thirty one (12.5%) children were rotavirus-
ELISA positive. The proportion of children with positive ELISAs
varied by month and was lower during the months of January to
June and higher from July to December (86/914 [9.4%] versus
145/695 [20.9%], respectively, p,0.01). This seasonal variation
became less well defined since 2009 and very few rotavirus cases
were detected in 2011 (Figure 1). The 2011 nadir however was
then followed by an increase in the number of cases in 2012, when
a much higher percentage of children had rotavirus.
The proportion of children with rotavirus by age and
vaccination status is shown in figure 2. In 2006, unvaccinated
children ,24 months were more likely to have rotavirus than
unvaccinated children $24 months old. Vaccinated children were
also less likely to have rotavirus than unvaccinated children. This
pattern changed after 2006, as a low percentage of both
vaccinated and unvaccinated children had rotavirus. The change
was observed in all age groups. The proportion of children with
severe episodes increased with age in both children with and
without rotavirus (p,0.001 for both) and children with rotavirus
had more severe episodes than children without rotavirus, as
shown in Figure 3. Generally, vaccinated children had less severe
episodes than unvaccinated children, but this difference was only
statistically significant in children ,6 months.
Two-hundred twenty seven rotavirus-ELISA positive stools
underwent G and P genotyping. Five G and three P types were
identified over the six years, as shown in Table 2. The most
prevalent G types were G2 (166, 73%), G1 (40, 17.6%) and G8
(13, 5.7%). Other G types identified included G3 (3, 1.5%), G12
(2, 0.9%) and four G non-typeable. The most frequent P types
were P[4] (179, 78.9%), P[8] (35, 15.4%) and P[6] (8, 3.5%), and
10 were non-typeable. The most common G and P combinations
were G2P[4] (160, 70.5%), G1P[8] (29, 12.7%), G8P[4] (12, 5.3%)
and G3P[8] (3, 1.3%). Less frequent combinations included
G1P[4] and G1P[6], G2P[6], G8P[6] and G12P[4] and G12P[8].
Five stools had more than one genotype, including two
G2P[4]P[8] and one each of G2G8P[1], G1G2P[4], with and
G8G2P[4]. The frequency of the genotypes varied over time.
G2P[4] was the only genotype identified from 2006 to 2009. Then
in 2009, the majority of rotaviruses were G1P[8], with G2P[4]
having a lower frequency. In 2010, G2P[4] was again the
Figure 1. Number of children enrolled and proportion with rotavirus infection by month, November 2006 to April 2012. The arrow
illustrates the date of vaccine introduction.
doi:10.1371/journal.pone.0110217.g001
Figure 2. Proportion of (a) non-vaccinated and (b) vaccinated
children attending the hospital with rotavirus, by age and
year. Percentages for 2012 are incomplete (to March, represented by a
dotted line). Arrows illustrate the vaccine introduction.
doi:10.1371/journal.pone.0110217.g002
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predominant genotype and other genotypes had lower frequencies.
A variety of genotypes were identified in 2011 but with low
frequencies, while seven of 14 isolates in 2012 belonged to the
uncommon G8P[4] genotype.
Surveillance data
All cause and diarrhoea-deaths occurring in children ,5 years
old in Brazil, Sergipe State and Aracaju from 1999 to 2012 are
shown in Figure 4 (a) and (b). All-cause deaths decreased
nationally from 81,391 deaths in 1999 to 45,101 in 2012 (45%
reduction from the 1999 baseline). Sergipe State recorded 1,511 in
1999 and 639 in 2012 (58% reduction) and Aracaju had the largest
percentage reduction with 450 deaths in 1999 and 167 in 2012
(63% reduction). The reduction trends for all-cause deaths were
similar between 1999–2005 and 2006–2012 nationally and at state
and city level.
Diarrhoea-specific deaths decreased more sharply than all-cause
deaths, with a national reduction from 4368 deaths in 1999 and
697 in 2012 (84% reduction) (p,0.001). Sergipe State reported
similar reductions, decreasing from 132 deaths in 1999 to 18 in
2012 (86% reduction). Aracaju city reported similar reductions,
from 11 deaths in 1999 to two in 2012 (82% reduction).
Percentage reductions in diarrhoea deaths were larger than for
all-cause deaths (p,0.001 for national, state and city level). The
decreasing trend for diarrhoea deaths were also different before
and after 2006 at the national level, with a 45% reduction from
1999 to 2005 and an additional 71% reduction from 2006 to 2012
(p,0.001). Sergipe reported a 36.4% reduction between 1999 and
2005 and 78% reduction from 2006 to 2012 (p,0.001). Diarrhoea
deaths therefore decreased more rapidly than all-cause deaths.
The proportion of all-cause deaths due to diarrhoea changed
nationally from 5.4% in 1999 to 1.5% in 2012. Similarly in
Sergipe and Aracaju, diarrhoea deaths represented 8.7% and
6.9% of all deaths in 1999, but only 2.8% and 1.2% in 2012
(Figure 4c).
Diarrhoea-related hospitalisations in Brazil, Sergipe and
Aracaju from 2003 to 2012 are shown in Figure 4d. Diarrhoea
hospitalizations decreased nationally from 89,934 in 2003 to
53,705 in 2012 (40.3% reduction). The percentage decrease was
also large in Sergipe and Aracaju, decreasing from 1729 to 748
(56.7% reduction) in Sergipe and from 483 to 296 (38.7%
reduction) in Aracaju. The reduction in the number of diarrhoea-
hospitalizations varied before and after vaccine introduction, with
a 1.7% reduction in the national number of hospitalizations from
2003 to 2005 and a 39.2% reduction between 2006 and 2012.
Similarly Sergipe State reported a 10% increase in diarrhoea
hospitalizations between 2003 and 2005 but a 56.7% reduction
between 2006 and 2012 (p,0.001).
Discussion
Diarrhoea is the second most important cause of child death
globally, with most cases occurring in low and middle income
countries and rotavirus is the pathogen most frequently associated
with severe episodes [13], incurring substantial hospitalisation,
medical consultations and parental costs [14]. The advent of
rotavirus vaccines and their rapid adoption by national immuni-
sation programmes heralded a new era of vaccine-based interven-
tions for diarrhoea control [1,2] with enormous potential for
health benefit. Brazil’s adoption of a rotavirus vaccine created one
of the largest rotavirus-vaccinated cohorts ever and monitoring
changes in the burden of rotavirus and all cause-diarrhoea in the
country could generate information for countries considering the
adoption of the vaccines.
This study demonstrates that Brazil experienced major epide-
miological changes in rotavirus-specific and all cause diarrhoea.
Figure 3. Proportion of vaccinated and non-vaccinated children attending the Emergency service with severe diarrhea, by age and
presence of rotavirus.
doi:10.1371/journal.pone.0110217.g003
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Surveillance data confirm the long term decline in all cause and
diarrhoea-specific childhood mortality [6,15], which have largely
been attributed to improved accessibility to services, sanitation and
public health interventions [15]. These trends are considerable
confounders to assess changes occurring after vaccine introduc-
tion. We therefore have described whether the secular trends
changed before and after vaccine introduction, and whether the
proportion of all deaths that are due to diarrhoea changed before
and after vaccine introduction. Both indicators suggest that the
vaccine introduction was associated with statistically significant
changes in the trends. Not only the number of diarrhoea deaths
decreased more rapidly after vaccine introduction, but the
proportion of diarrhoea became a smaller proportion of all deaths.
Nationally, the proportion of deaths attributed to diarrhoea
declined from 5.4% of all deaths in 1999 to 3.9% by 2005, but
changed again from 3.9% in 2005 to 1.5% in 2012. The same
pattern was observed for Sergipe, with a 36% reduction in the
number of episodes between 1999 and 2005 and a 78% reduction
after vaccine introduction, with the proportion of childhood deaths
due to diarrhoea reducing from 8.2% in 2005 to 2.5% in 2012.
The patterns therefore strongly suggest that these changes are due
to the vaccine and the higher proportion of diarrhoea deaths in
Sergipe is in agreement with previous data reporting a higher
diarrhoea mortality in the Northeast of the country[6].
Data for diarrhoea-related hospitalizations were only available
from 2002 and secular trends before vaccine introduction were less
well documented. However the data suggests that changes in the
number of hospitalizations before vaccine introduction were
minimal. These trends had an evident change after vaccine
introduction, with a 39.2% national reduction in diarrhoea-related
hospitalization and an even larger 56.7% reduction in Sergipe.
These data thus confirm that the vaccine is associated with
significant reductions in hospitalizations and that these reductions
were higher in a state where diarrhoea was a significant public
health problem. Reductions in diarrhoea-related deaths and
hospitalisations have been reported from Latin America [16],
the United States [17], Europe [18,19] and Australasia [20] and
interestingly these reductions have been higher than expected
from previous impact models, which has been attributed to many
cases being undetected before vaccine introduction and a
sustained vaccine efficacy over several years [21].
Our hospital data show that the proportion of children with
rotavirus infection has also decreased over the years, with a
remarkable low proportion of cases having rotavirus in 2011. This
low proportion was observed in both vaccinated and unvaccinated
children and in infants and older children. Although counterin-
tuitive, our findings are in agreement with reports demonstrating
the significant herd protection of the vaccine [22,23], which is
likely due to the reduced virus transmission in the environment
and possibly vaccine strains spreading to unvaccinated children
[24].
Our study also documents changes in the rotavirus genotypes. A
high proportion of G2P[4] strains from 2006 to 2010 had been
reported by us and others in Brazil and by countries that use the
Rotarix vaccine in Australasia [20] and Europe [19,22,25]. We
have however also observed further changes in 2011, when the
G2P[4] became less frequent and other strains, such as G8[4],
G8P[6] and G3P[8)] became more frequent. The G2P[4] decrease
and the increase of other unusual G8 strains suggest that these
changes may not be limited to the G2P[4] genotype. G8 is
considered to have a bovine origin and is not included in the
current vaccines [26] and has frequently been reported from
African countries, where it accounts for about 12% of cases [27]
and has recently been reported from Europe [28]. A further
genotype increasingly isolated in 2011/12 was G3P[8]. This
genotype has been reported with increased frequency in regions
with a high coverage of RotaTeq [10], but it is also one of the five
globally common rotavirus genotypes and its significance in the
Brazilian context needs further study.
Figure 4. Childhood (,5 years old) all cause and diarrhea
deaths and hospitalizations in Brazil, Sergipe and Aracaju City.
Arrows illustrate the year of vaccine introduction.
doi:10.1371/journal.pone.0110217.g004
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It is also interesting that despite the reduced mortality and
hospitalizations, the proportion of diarrhea episodes classified as
severe has increased over the years. This increase occurred both in
vaccinated and unvaccinated children and in children with and
without rotavirus. This might be an artefact caused by self-
selection of patients, changes in service organization and provision
and older children becoming more prominent because younger
children are protected by the vaccine. In addition, other pathogens
not included in this analysis (e.g. norovirus) may become more
established and further studies are needed to establish if other
pathogens may take the ecological niche of rotavirus.
Our study also has important limitations. The evaluation was
partly conducted using data collected through surveillance
systems, which are not devoid of problems. Surveillance is often
based on sentinel sites that may change over time and become
unrepresentative and incomplete data reporting may underesti-
mate the mortality and hospitalizations attributed to diarrhoea.
Furthermore, using all-cause diarrhoea as a marker for rotavirus
diarrhoea could mask changes in the epidemiology of other
pathogens. In addition, the hospital case series only recorded a
child as vaccinated if both doses of the vaccine were recorded, and
not vaccinated if the child had received none or one vaccine dose.
Labelling partially vaccinated children as unvaccinated could have
reduced the number of episodes in the non-vaccinated group.
However rotavirus infections were uncommon in all children and
very few of the children receive only one dose of the vaccine, and
for these reasons we believe this limitation is unlikely to modify the
interpretation of the data. Furthermore, children admitted to the
hospital outside working hours were assessed the following
morning, but ambulatory children attending at night were missed.
If attendance patterns and genotype distributions were associated
with clinical severity, then this sampling strategy could have led to
bias towards children with mild or severe presentations and the
exclusion of children with moderate diarrhea and distortions in the
genotype distribution.
Despite these shortcomings, similar approaches are being used
to monitor vaccine efficacy elsewhere and African countries are
preparing to use this method to monitor the vaccines when
introduced on a large scale in the continent [29–31].
Table 2. Genotypes identified in children attending the emergency hospital with diarrhea (2006–2012).
ELISA-positive/tested Genotype N (%)
2006 18/73 (25%) G2P[4] 16 (89)
GNTP4 1 (6)
G2PNT 1 (6)
2007 30/324 (9.3%) G2P[4] 28 (93)
GNTPNT 2 (7)
2008 77/416 (18.5%) G2P[4] 77 (100)
2009 41/384 (10.7%) G1P[8] 28 (68)
G2P[4] 9 (22)
G2P[4]P[8] 1 (2)
G2PNT 2 (5)
GNTPNT 1 (2)
2010 40/335 (11.9%) G2P[4] 26 (65)
G1P[6] 4 (10)
G1P[4] 3 (8)
G2P[6] 2 (5)
G2P[4]P[8] 1 (3)
G1P[8] 1 (3)
G8P[4] 1 (3)
G12P[8] 1 (3)
G12P[4] 1 (3)
2011 8/207 (3.9%) G2P4 2 (25)
G3P[8] 2 (25)
G8P[4] 2 (25)
G2G8P[4] 1 (13)
G2PNT 1 (13)
2012 13/70 (18.5%) G8P[4] 7 (54)
G8P[6] 2 (15)
G1G2P[4] 2 (15)
G3P[8] 1 (8)
G8G2P[4] 1 (8)
All 227/1809 (12.5%)
doi:10.1371/journal.pone.0110217.t002
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A further limitation is that our prospective data collection was
based in one medical centre, receiving both self-selected and
referred cases and therefore genotype representation is likely to be
biased towards children with more severe episodes.
Despite these limitations, the data presented here add to the
evidence of the growing public health impact of rotavirus vaccines
in Brazil, with large reductions in the number of diarrhoea related
childhood hospitalizations and deaths. Our data also provide new
evidence that the predominance of the G2P[4] genotype in
countries using the monovalent rotavirus vaccine is temporal and
that other unusual genotypes may appear with time. Continued
surveillance therefore is needed to document the continued
effectiveness of the vaccines and the potential emergence of
unusual rotavirus genotypes.
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